Eupraxia Pharmaceuticals Inc. (EPRX) Financials

EPRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 139.6 million 10.2 million
March 31, 2026 145.4 million 9.2 million
Dec. 31, 2025 86.2 million 5.7 million
Sept. 30, 2025 92.3 million 3.9 million

EPRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -13.2 million ?
March 31, 2026 -10.3 million 2.3 million
Dec. 31, 2025 -10.1 million 6.0 million
Sept. 30, 2025 -3.3 million 319849

EPRX Net Income

No data available :(

EPRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 133.4 million - 1.8 million
March 31, 2026 138.9 million - 2.0 million
Dec. 31, 2025 80.6 million - 154362
Sept. 30, 2025 89.0 million - 170603

EPRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 66.2 million
March 31, 2026 56.7 million
Dec. 31, 2025 51.9 million
Sept. 30, 2025 36.9 million

EPRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 172755 12.8 million 5.3 million -
March 31, 2026 322426 11.2 million 4.8 million -
Dec. 31, 2025 196292 7.9 million 8.3 million -
Sept. 30, 2025 43289 3.2 million 1.8 million -

EPRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - 131508
March 31, 2026 - 88897
Dec. 31, 2025 - 73864
Sept. 30, 2025 - 62286

EPRX

Price: $6.76

52 week price:
5.04
9.32

Earnings Per Share: -1.04 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 449.5 million

Links: